Appropriate use of bone densitometry.

Genant, Harry K.; Block, Jon E.; Steiger, Peter; Glueer, Claus-Christian; Ettinger, Bruce; Harris, S. T.

doi:10.1148/radiology.170.3.2916037

Cited by 153 publications

(45 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the correlation between calcaneal bone mineral density as measured by DXA and L3 bone mineral density determined by dualenergy quantitative CT was moderate, and the decrement rates for women were different between these bones, suggesting that some limitations may exist when calcaneal bone mineral density is used to assess osteopenia. DXA has several advantages over dual-energy quantitative CT because it offers a lower absorbed dose and better precision than dual-energy quantitative CT does [4]. However, in the spine and femoral neck, which are the preferential sites for bone mineral assessment, DXA measures both the trabecular and cortical portions of the bone.…”

Section: Discussionmentioning

confidence: 99%

Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers.

Yamada

Ito²,

Hayashi³

et al. 1993

American Journal of Roentgenology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers.

Yamada

Ito²,

Hayashi³

et al. 1993

American Journal of Roentgenology

View full text Add to dashboard Cite

“…The study by Riggs et al [3], demonstrated that the restoration of bone mass with fluoride did not necessarily result in a reduction of fracture rate. On the other hand, in osteoporotic patients a 20%-50% decrease in incidence of new vertebral crush fractures after 2 years treatment has been evidenced by several open prospective studies using the same doses of NaF (50 mg/d) as in our study [9,[14][15][16][17][18]. Thus the crucial question of the anti-fracture effect of NaF remains debatable.…”

Section: Discussionmentioning

confidence: 54%

“…The long-term coefficient of variation (18 months) assessed in young subjects was 2 2 2.2% (0.024 g/cm ) for L2-L4, 1.5% (0.014 g/cm ) for femoral neck and 2.8% (0.021 g/cm 2) for the trochanter [8]. Therefore a variation in vertebral bone density of more than ___ 0.043 g/cm 2 (90% one-tailed confidence limit) between two examinations was considered significant [9].…”

Section: Methodsmentioning

confidence: 98%

Fluoride therapy in postmenopausal osteopenic women: Effect on vertebral and femoral bone density and prediction of bone response

Pouillès¹,

Tremollieres²,

Caussé

et al. 1991

Osteoporosis Int

View full text Add to dashboard Cite

Fifty-two postmenopausal women (mean age 60 +/- 5 years) with low BMD (less than -2SD of young adult values) but who had not experienced previous crush fracture were treated with 50 mg of sodium fluoride (NaF), 1 g of calcium and 400 IU of vitamin D2 per day for 2 years. Repeated vertebral and femoral BMD measurements were made and compared with those of a control group consisting of 16 untreated women. Serum alkaline phosphatase and osteocalcin, blood and urinary fluoride levels were measured regularly to determine their predictive value on bone response. 18 of 52 (35%) of the treated patients experienced side effects (29% gastric, 4% lower extremity pain syndrome) but only in 6 cases (12%) was it necessary to discontinue treatment. In neither of the two groups was any fracture recorded (vertebral or otherwise). Among the 43 women who were treated for at least 2 years, 21 (49%) were considered to have responded (i.e., with an increase of vertebral BMD greater than 0.043 g/cm2). There was a mean linear increase in BMD in this group of 0.0041 g/cm2 per month (i.e., 5.5% per year). On the other hand in the non-responder group and in the control group, vertebral BMD either remained stable or decreased. However no difference was detected between the two groups (treated and controls) at the femoral site after 2 years; both groups showed a significant decrease in BMD. The responders had a lower initial osteocalcin level and treatment led to a relatively greater increase in osteocalcin.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

“…In recent years, many techniques have been developed for examining bone disease including the measurement of intact parathyroid hormone molecule by radioimmunoassay [21], serum bone alkaline phosphatase, quantitative computed tomography scan and bone density and mineral content by single or dual photon densitometry [22, 23]. Significant correlation of bone histology with i-PTH has been well reported.…”

Section: Discussionmentioning

confidence: 99%

Renoprotection following Treatment of Secondary Hyperparathyroidism with Percutaneous Ethanol Injection in Pre-Dialysis Patients

Chen

Chen²,

Yeh³

2002

Nephron

View full text Add to dashboard Cite

What could be done for patients with chronic renal failure are marginally beneficial. Among 58 pre-dialysis patients, we found 24 of chronic glomerulonephritis (CGN) with serum creatinine >5 mg/dl and intact parathyroid hormone (i-PTH) >200 pg/ml. In this study, we determined if the residual renal function could be preserved when hyperparathyroidism was corrected by either low-dose calcitriol treatment or ethanol injection. The 58 CGN patients were divided into three groups. The first group, which comprised 11 cases with i-PTH >200 pg/ml and had parathyroid mass, were treated by ultrasonography-guided percutaneous ethanol injection therapy (PEIT). The second study group composed of 13 cases with i-PTH >200 pg/ml without parathyroid mass were treated by calcitriol 1 µg every other day. The third group made up of 34 cases with i-PTH <200 pg/ml, who did not receive calcitriol or ethanol therapy. All patients were followed up within 2 years or until dialysis. The average rate of decline in renal function (slope of reciprocal serum creatinine vs. time) was 0.0025 ± 0.0026 dl/mg month in group 1, 0.0054 ± 0.0024 in group 2, and 0.0067 ± 0.0025 in group 3 (p = 0.018 in group 1 vs. group 2, p < 0.001 in group 1 vs. group 3). The declines of i-PTH, phosphorus, and alkaline phosphatase, and the increase of calcium were all significantly different between group 1 and group 3. Two cases of group 1, 6 cases of group 2, and 20 cases of group 3 entered into dialysis during this study. In conclusion, selective PEIT guided by color Doppler flow mapping is an effective therapy for treating hyperparathyroidism and protecting the residual renal function.

show abstract

Appropriate use of bone densitometry.

Cited by 153 publications

References 0 publications

Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers.

Calcaneus as a site for assessment of bone mineral density: evaluation in cadavers and healthy volunteers.

Fluoride therapy in postmenopausal osteopenic women: Effect on vertebral and femoral bone density and prediction of bone response

Renoprotection following Treatment of Secondary Hyperparathyroidism with Percutaneous Ethanol Injection in Pre-Dialysis Patients

Contact Info

Product

Resources

About